Alnylam Pharmaceuticals (ALNY) Short Interest Ratio & Short Volume

Short interest is the volume of Alnylam Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 3,700,000 shares of ALNY short. Learn More on Alnylam Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALNY shares currently have a short interest ratio of 5.0. Learn More on Alnylam Pharmaceuticals's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Alnylam Pharmaceuticals: Barclays PLC, Jane Street Group LLC, Wolverine Trading LLC, Parallax Volatility Advisers L.P., Melqart Asset Management UK Ltd, Cinctive Capital Management LP, Paloma Partners Management Co, Garda Capital Partners LP, Walleye Trading LLC, Walleye Capital LLC, PEAK6 Investments LLC, Citigroup Inc., Wolverine Asset Management LLC, and Portman Square Capital LLP. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Alnylam Pharmaceuticals saw a decline in short interest in October. As of October 31st, there was short interest totaling 3,700,000 shares, a decline of 23.6% from the previous total of 4,840,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies compare to Alnylam Pharmaceuticals: BeiGene, Ltd. (1.12%), Royalty Pharma plc (3.84%), Sarepta Therapeutics, Inc. (5.86%), Catalent, Inc. (4.65%), Elanco Animal Health Incorporated (2.81%), Vertex Pharmaceuticals Incorporated (1.75%), Gilead Sciences, Inc. (1.43%), Regeneron Pharmaceuticals, Inc. (1.68%), Biogen Inc. (2.16%), United Therapeutics Co. (5.24%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

Short selling ALNY is an investing strategy that aims to generate trading profit from Alnylam Pharmaceuticals as its price is falling. ALNY shares are trading down $22.35 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Alnylam Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ALNY, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALNY, twice per month. The most recent reporting period available is October, 31 2024.